Developmental Therapeutics Program

One Dose Mean Graph

NSC: 766305 / 1	Conc: 1.00E-5 Molar	Test Date: Jul 30, 2012
Experiment ID: 1207OS20		Report Date: Oct 12, 2012

Panel/Cell Line	Growth Percent
Leukemia	
CCRF-CEM	90.31
HL-60(TB)	96.25
K-562	94.92
MOLT-4	98.07
RPMI-8226	91.34
SR	84.09
Non-Small Cell Lung Cancer	
A549/ATCC	97.11
HOP-62	99.91
NCI-H226	93.34
NCI-H23	97.30
NCI-H322M	94.78
NCI-H460	101.88
NCI-H522	94.55
Colon Cancer	
COLO 205	106.05
HCC-2998	120.04
HCT-116	101.96
HCT-15	99.10
HT29	105.28
SW-620	102.28
CNS Cancer	
SF-268	91.11
SF-295	98.12
SF-539	101.49
SNB-19	99.12
SNB-75	75.62
U251	95.46
Melanoma	
LOX IMVI	95.00
MALME-3M	103.80
M14	97.79
MDA-MB-435	111.32
SK-MEL-2	92.84
SK-MEL-28	110.44
SK-MEL-5	96.33
UACC-257	91.05
UACC-62	106.34
Ovarian Cancer	
IGROV1	102.28
OVCAR-3	101.83
OVCAR-4	96.83
OVCAR-5	100.47
OVCAR-8	103.73
NCI/ADR-RES	101.35
SK-OV-3	105.48
Renal Cancer	
786-0	97.42
A498	89.48
ACHN	103.59
CAKI-1	97.19
RXF 393	100.24
SN12C	97.92
TK-10	107.52
UO-31	89.35
Prostate Cancer	
PC-3	91.76
DU-145	104.40
Breast Cancer	
MCF7	97.37
MDA-MB-231/ATCC	104.37
HS 578T	104.94
BT-549	99.76
T-47D	86.35
MDA-MB-468	86.74
Mean	98.33
Delta	22.71
Range	44.42

Mean Growth Percent - Growth Percent